|
1
|
Yi R and Fuchs E: MicroRNAs and their
roles in mammalian stem cells. J Cell Sci. 124:1775–1783. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gusev Y: Computational methods for
analysis of cellular functions and pathways collectively targeted
by differentially expressed microRNA. Methods. 44:61–72. 2008.
View Article : Google Scholar
|
|
3
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar
|
|
4
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akao Y, Nakagawa Y and Naoe T:
MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 26:311–320.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Z, Zeng H, Guo Y, et al: miRNA-145
inhibits non-small cell lung cancer cell proliferation by targeting
c-Myc. J Exp Clin Cancer Res. 29:1512010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Y, Liu S, Xin H, et al: Up-regulation
of microRNA-145 promotes differentiation by repressing OCT4 in
human endometrial adenocarcinoma cells. Cancer. 117:3989–3998.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins - therapeutic potential in cancer. Curr Cancer Drug
Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kheradmand F and Werb Z: Shedding light on
sheddases: role in growth and development. Bioessays. 24:8–12.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wildeboer D, Naus S, Amy Sang QX, Bartsch
JW and Pagenstecher A: Metalloproteinase disintegrins ADAM8 and
ADAM19 are highly regulated in human primary brain tumors and their
expression levels and activities are associated with invasiveness.
J Neuropathol Exp Neurol. 65:516–527. 2006. View Article : Google Scholar
|
|
12
|
Zheng X, Jiang F, Katakowski M, et al:
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell
invasiveness. Cancer Sci. 98:674–684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng X, Jiang F, Katakowski M, et al:
Sensitization of cerebral tissue in nude mice with photodynamic
therapy induces ADAM17/TACE and promotes glioma cell invasion.
Cancer Lett. 265:177–187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsatas D, Kanagasundaram V, Kaye A and
Novak U: EGF receptor modifies cellular responses to hyaluronan in
glioblastoma cell lines. J Clin Neurosci. 9:282–288. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gregersen LH, Jacobsen AB, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-145 targets YES and STAT1 in colon
cancer cells. PLoS One. 5. pp. e88362010, View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takagi T, Iio A, Nakagawa Y, Naoe T,
Tanigawa N and Akao Y: Decreased expression of microRNA-143 and
-145 in human gastric cancers. Oncology. 77:12–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akao Y, Nakagawa Y, Kitade Y, Kinoshita T
and Naoe T: Downregulation of microRNAs-143 and -145 in B-cell
malignancies. Cancer Sci. 98:1914–1920. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ichimi T, Enokida H, Okuno Y, et al:
Identification of novel microRNA targets based on microRNA
signatures in bladder cancer. Int J Cancer. 125:345–352. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fischer L, Hummel M, Korfel A, Lenze D,
Joehrens K and Thiel E: Differential micro-RNA expression in
primary CNS and nodal diffuse large B-cell lymphomas.
Neurooncology. 13:1090–1098. 2011.PubMed/NCBI
|
|
21
|
Fang X, Yoon JG, Li L, et al: The SOX2
response program in glioblastoma multiforme: an integrated
ChIP-seq, expression microarray, and microRNA analysis. BMC
Genomics. 12:112011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lo HW: EGFR-targeted therapy in malignant
glioma: novel aspects and mechanisms of drug resistance. Curr Mol
Pharmacol. 3:37–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng X, Jiang F, Katakowski M, Lu Y and
Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol
Carcinog. 51:150–164. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung
adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hart S, Fischer OM and Ullrich A:
Cannabinoids induce cancer cell proliferation via tumor necrosis
factor alpha-converting enzyme (TACE/ADAM17)-mediated
transactivation of the epidermal growth factor receptor. Cancer
Res. 64:1943–1950. 2004. View Article : Google Scholar
|
|
26
|
Lee DC, Sunnarborg SW, Hinkle CL, et al:
TACE/ADAM17 processing of EGFR ligands indicates a role as a
physiological convertase. Ann NY Acad Sci. 995:22–38. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Laerum OD, Nygaar SJ, Steine S, et al:
Invasiveness in vitro and biological markers in human primary
glioblastomas. J Neurooncol. 54:1–8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wells A: EGF receptor. Int J Biochem Cell
Biol. 31:637–643. 1999. View Article : Google Scholar
|
|
29
|
Kornfeld JW, Meder S, Wohlberg M, et al:
Overexpression of TACE and TIMP3 mRNA in head and neck cancer:
association with tumour development and progression. Br J Cancer.
104:138–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Narita D, Seclaman E, Ursoniu S and Anghel
A: Increased expression of ADAM12 and ADAM17 genes in laser-capture
microdissected breast cancers and correlations with clinical and
pathological characteristics. Acta Histochem. 114:131–139. 2012.
View Article : Google Scholar
|
|
31
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blanchot-Jossic F, Jarry A, Masson D, et
al: Up-regulated expression of ADAM17 in human colon carcinoma:
co-expression with EGFR in neoplastic and endothelial cells. J
Pathol. 207:156–163. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin P, Sun X, Feng T, et al: ADAM17
regulates prostate cancer cell proliferation through mediating cell
cycle progression by EGFR/PI3K/AKT pathway. Mol Cell Biochem.
359:235–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katakowski M, Jiang F, Zheng X, Gutierrez
JA, Szalad A and Chopp M: Tumorigenicity of cortical astrocyte cell
line induced by the protease ADAM17. Cancer Sci. 100:1597–1604.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heimberger AB, Hlatky R, Suki D, et al:
Prognostic effect of epidermal growth factor receptor and EGFRvIII
in glioblastoma multiforme patients. Clin Cancer Res. 11:1462–1466.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mukasa A, Wykosky J, Ligon KL, Chin L,
Cavenee WK and Furnari F: Mutant EGFR is required for maintenance
of glioma growth in vivo, and its ablation leads to escape from
receptor dependence. Proc Natl Acad Sci USA. 107:2616–2621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tysnes BB, Haugland HK and Bjerkvig R:
Epidermal growth factor and laminin receptors contribute to
migratory and invasive properties of gliomas. Invasion Metastasis.
17:270–280. 1997.PubMed/NCBI
|
|
38
|
Cho WC, Chow AS and Au JS: MiR-145
inhibits cell proliferation of human lung adenocarcinoma by
targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Franovic A, Robert I, Smith K, et al:
Multiple acquired renal carcinoma tumor capabilities abolished upon
silencing of ADAM17. Cancer Res. 66:8083–8090. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lal A, Glazer CA, Martinson HM, et al:
Mutant epidermal growth factor receptor up-regulates molecular
effectors of tumor invasion. Cancer Res. 62:3335–3339.
2002.PubMed/NCBI
|
